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Background-—The electrocardiographic interatrial block (IAB) has been associated with atrial ﬁbrillation (AF). We aimed to test
whether IAB can improve risk prediction of AF for the individual person.
Methods and Results-—Digital ECGs of 152 759 primary care patients aged 50 to 90 years were collected from 2001 to 2011. We
identiﬁed individuals with P-wave ≥120 ms and the presence of none, 1, 2, or 3 biphasic P-waves in inferior leads. Data on comorbidity,
medication, and outcomes were obtained from nationwide registries. We observed a dose-response relationship between the number
of biphasic P-waves in inferior leads and the hazard of AF during follow-up. Discrimination of the 10-year outcome of AF, measured by
time-dependent area under the curve, was increased by 1.09% (95% conﬁdence interval 0.43–1.74%) for individuals with
cardiovascular disease at baseline (CVD) and 1.01% (95% conﬁdence interval 0.40–1.62%) for individuals without CVD, when IAB was
added to a conventional risk model for AF. The highest effect of IAB on the absolute risk of AF was observed in individuals aged 60 to
70 years with CVD. In this subgroup, the 10-year risk of AF was 50% in those with advanced IAB compared with 10% in those with a
normal P-wave. In general, individuals with advanced IAB and no CVD had a higher risk of AF than patients with CVD and no IAB.
Conclusions-—IAB improves risk prediction of AF when added to a conventional risk model. Clinicians may consider monitoring
patients with IAB more closely for the occurrence of AF, especially for high-risk subgroups. ( J Am Heart Assoc. 2018;7:e008247.
DOI: 10.1161/JAHA.117.008247.)
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T he electrocardiographic interatrial block (IAB) typicallyexists when a conduction delay over the Bachmann’s
bundle is present, however, it can also be caused by intra-atrial
conduction delay and left atrial enlargement. By analogy to
other types of block, there is a continuum of IAB severity; partial
IAB is deﬁned as a P-wave duration ≥120 ms and advanced IAB
is deﬁned as P-wave duration ≥120 ms in conjunction with
biphasic P-wave morphology in inferior leads II, III, and aVF.1
There has been an increasing interest in IAB in recent years,
especially regarding its role in atrial ﬁbrillation (AF) and
ischemic stroke.2 In previous prospective studies of the general
population (N15 000), advanced IAB (yes/no) has been
associated with an increased risk of AF and ischemic stroke.3,4
The observed increased risk of ischemic stroke was reported to
be independent of AF as an intermediate step.4 For this reason,
questions have been raised whether treatment with
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anticoagulation therapy in patients with IAB could be beneﬁcial,
regardless of AF status.4,5 However, to properly assess the
clinical utility of a parameter with regards to risk stratiﬁcation,
knowledge on the absolute risks of AF and ischemic stroke
associated with IAB is needed. Moreover, whether IAB is of
clinical value in long-term risks of AF and ischemic stroke on an
individual level has not been investigated.
Using a large middle-aged and elderly population of
primary care patients, we aimed to: (1) replicate earlier
ﬁndings of an association between IAB and an increased risk
of AF and ischemic stroke; (2) examine differences in hazards
according to the number of biphasic P-waves in inferior leads;
(3) investigate whether IAB is associated with conduction
disorder and death from all causes; (4) evaluate whether IAB
is of value in personalized long-term risk prediction of AF and
ischemic stroke; (5) to estimate absolute risks of AF and
ischemic stroke based on IAB across clinically relevant
subgroups, and ﬁnally; (6) to describe the association
between IAB and left atrial end-diastolic volume.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
This study is part of the Copenhagen ECG study encompass-
ing all people who had an ECG recorded at the Copenhagen
General Practitioners’ Laboratory in the period 2001 to 2011,
as described in details previously.6 For the present analyses,
we excluded individuals with the following characteristics at
baseline: <50 or ≥90 years of age, AF, ischemic stroke,
treatment with class I or III anti-arrhythmic drugs, treatment
with warfarin or non–vitamin K antagonist oral anticoagulants,
and pacemaker or implantable cardioverter-deﬁbrillator. Addi-
tionally, we excluded individuals with ECG ﬁndings inconsis-
tent with interpretation of the IAB as noted in the
Electrocardiography section.
According to Danish law, no approval from an ethics
committee is needed in a registry-based study without any
active participation from study subjects. The use of deiden-
tiﬁed registry data was approved by the Danish Data
Protection Agency.
Electrocardiography
All ECGs recorded at the Copenhagen General Practitioners’
Laboratory were digitally stored in the MUSE Cardiology
Information System, and processed using version 21 of the
Marquette 12SL algorithm (GE Healthcare, Wauwatosa, WI).6
The Marquette 12SL algorithm is a ECG analysis program.7
Using the 12SL algorithm, we excluded ECGs with rhythms
different from sinus rhythm, multiple premature atrial or
ventricular complexes, second- and third-degree atrioventric-
ular blocks, heart rates <30 or >120 bpm, pace spikes, and
ventricular preexcitation.6 We divided the population into 5
categories based on IAB; normal P-wave duration (<120 ms),
partial IAB (P-wave duration ≥120 ms and no biphasic [plus/
minus] P waves in inferior leads) and 3 groups of IAB (P-wave
duration ≥120 ms) associated with biphasic (plus/minus) P-
waves in 1, 2, or 3 inferior leads (II, III, and aVF), the latter
representing the strictly deﬁned advanced IAB.1,2 P-wave
duration was obtained as previously described,8 corresponding
to the interval between the earliest detection of atrial
depolarization in any lead and the latest detection of atrial
depolarization in any lead. Amplitudes of signiﬁcant waves
within the P-wave are measured with respect to a baseline level
that is interpolated from P onset to P offset. A wave crossing the
baseline level which constitutes an area of ≥160 lV-ms is
considered a separate and signiﬁcant wave. The 12SL algorithm
accommodates the phenomena of PR-interval depression. As
such, IAB was deﬁned by ourselves based on the 12SL
algorithm’s measurements of lead-speciﬁc amplitudes and
global P-wave duration. Examples of IAB according to number of
biphasic P-waves in inferior leads are illustrated in Figure 1. In a
supplemental analysis, we also divided the population into eight
categories based on which inferior leads, or combination of
leads, were affected by a biphasic P-wave. We found excellent
agreement between the 12SL algorithm and manual interpre-
tation in the detection of IAB. We did an enriched random
sampling of 25 normal ECGs, 25 with partial IAB, 25 with IAB
Clinical Perspective
What Is New?
• Electrocardiographic interatrial block (IAB) improves risk
prediction of atrial ﬁbrillation on an individual level;
however, IAB does not seem to improve risk prediction of
ischemic stroke.
• In general, individuals with advanced IAB and no cardiovas-
cular disease had a higher risk of atrial ﬁbrillation than
patients with cardiovascular disease and no interatrial
block.
What Are the Clinical Implications?
• Clinicians may consider intensiﬁed monitoring of patients
with IAB for the occurrence of atrial ﬁbrillation, especially if
the block is advanced with biphasic P-waves in all inferior
electrocardiographic leads.
• We would argue against initiating anticoagulation treatment
merely on the presence of IAB, as suggested by others.
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and 1 biphasic P-wave in inferior leads, 25 with IAB and 2
biphasic P-waves in inferior leads, and 25 with advanced IAB
and 3 biphasic P-waves in inferior leads all detected by 12SL.
Extraction of ECGs for the purpose of manual validation was
done by C.G., manual interpretation of the ECGs blinded to the
12SL interpretation was done by M.W.S., and comparison
between 12SL detected IAB andmanual detected IAB was done
by J.B.N. We observed an unweighted and weighted kappa of
0.98 (0.95–0.98) and 1.0 (0.99–1.0), respectively.
Baseline Variables and Follow-Up
All people with permanent residence in Denmark are allocated
a unique and personal identiﬁcation number which enables
linkage of data across multiple nationwide healthcare reg-
istries. This makes it possible to gather information on death,
emigration, the use of prescription medication and any
hospital, outpatient clinic, or emergency room discharge
diagnosis on an individual level.9
Individuals with the following characteristics at baseline
were identiﬁed: hypertension, valvular heart disease,
ischemic heart disease, heart failure (HF), diabetes mellitus,
hyperthyroidism, obesity, sleep apnea, and anti-platelet use.
Hypertension was deﬁned from discharge diagnosis or if a
subject before inclusion was treated simultaneously with at
least 2 types of antihypertensive drugs.10 Valvular heart
disease was deﬁned from discharge diagnosis, procedure,
and operation codes.10 Ischemic heart disease was deﬁned
from discharge diagnoses of stabile angina pectoris or acute
coronary syndrome. HF was deﬁned as a discharge diagnosis of
HF in combination with treatment with loop diuretics.10
Diabetes mellitus and hyperthyroidism were deﬁned from
discharge diagnosis or in case of a purchase of prescription
medication used for 1 of the 2 diseases. Obesity was deﬁned
from discharge diagnosis.11 Anti-platelet use was deﬁned from
dispensed prescriptions. AF was the outcome of primary
interest and was deﬁned from hospital, outpatient clinic, or
emergency room discharge diagnoses.10 Secondary end points
were ischemic stroke, death from all causes and a combined
end point of sick sinus node syndrome and third degree atrio-
ventricular block, named “conduction disorder” hereafter.
Detailed information on the identiﬁcation of covariates and
clinical outcomes in the Danish registries is available in Tables
S1 and S2. Follow-up began on the day of the ﬁrst ECG
recording (index ECG) and ended in case of the event of
interest, death, emigration, or at December 31, 2013,
whichever occurred ﬁrst.
Cardiac Computed Tomography Scan Population
To determine the relationship between left atrial size and IAB,
we included data from a population with available contrast
enhanced low-dose cardiac computed tomography (CT) scans
and digital ECGs. These individuals, randomly sampled from
the general population in Copenhagen, were participants in
the Copenhagen General Population Study.12
Figure 1. Examples of interatrial block as well as a normal ECG. IAB indicates interatrial block.
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All cardiac CT scans were obtained in late diastole just
before atrial contraction. Left atrial volume was manually
assessed, as described in details previously.13 A high degree
of agreement with magnetic resonance imaging as well as a
low interobserver variability has been observed.13
Written informed consent was obtained from all partici-
pants, and the study was approved by the local ethics
committee (H-KF-01-144/01).
Statistical Analyses
Time-on-study was used as timescale in all survival analyses.
The median follow-up time was estimated with the reverse
Kaplan-Meier method.14
A 2-sided P<0.05 was considered statistically signiﬁcant.
All analyses were conducted with the use of Stata 14.0
software package (StataCorp LP, College Station, TX) and R (R
Foundation for Statistical Computing, Vienna, Austria [URL
http://www.R-project.org/]).
Association Analyses
Cause-speciﬁc Cox regression was used to assess the
association of IAB on the index ECG with the hazard rate of
AF, ischemic stroke, conduction disorder, and death, respec-
tively, during follow-up. All Cox models were adjusted for age,
sex, hypertension, valvular heart disease, ischemic heart
disease, HF, diabetes mellitus, hyperthyroidism, obesity, sleep
apnea, anti-platelet use, heart rate (categorized into tertiles),
and Sokolow-Lyon ECG criteria of left ventricular hypertrophy.
The category with a P-wave duration <120 ms (normal P-wave
duration) was chosen as reference. In supplemental analyses
individuals with 1 or 2 biphasic P-waves were further
subdivided regarding which leads were affected. In this
setting, the combination of 2 biphasic P-waves in leads II and
III were excluded as only 6 individuals had this combination of
2 biphasic P-waves.
As a sensitivity analysis, the direct association between
IAB and the risk of ischemic stroke, independent of AF as a
possible intermediate step, was assessed by censoring
individuals in case of incident AF.
Risk Prediction
Risk prediction analyses were conducted for 10-year outcome
separately for individuals with and without cardiovascular
disease (CVD) at baseline. CVD was deﬁned as present if any
of the following was present at baseline; valvular heart disease,
HF, ischemic heart disease, or hypertension. The 10-year risks
of AF and ischemic stroke were predicted in a competing risk
setting by combining a Cox model for all-cause mortality and a
Cox model for the outcome of interest.15 The time-dependent
area under the receiving operating characteristics curve (AUC)
was calculated to evaluate the added discriminative value of IAB
for the purpose of AF- and ischemic stroke-speciﬁc risk
prediction.16 AUC corresponds to the probability that a person
who experiences the event of interest (AF or ischemic stroke)
within 10 years receives a higher predicted risk than that of a
person who does not (dies or is alive 10 years after ECG). To
estimate the 10-year AUC, we split the data into a training set
(63%) and test set (37%). Since the results of this approach may
depend on how the data are split, we split the data set 1001
times at random and then reported results for the split which
corresponds to themedianAUC in the1001modelswithout IAB.
Differences in AUC between models with and without IAB were
calculated to assess the effect of adding IAB to conventional risk
models for AF and ischemic stroke. Brier scoreswere calculated
to evaluate model calibration.17 To illustrate the time-trends of
the predicted risks of AF and ischemic stroke, we calculated the
average risks within 10-year age-groups for all combinations of
CVD/no CVD and IAB pattern. Predictions for cumulative
incidence curves were based on multivariable-adjusted Cox
models ﬁtted within the respective 10-year age-group and CVD
subgroup (yes/no). Age within the various 10-year age-groups
was included as a covariate.
Relationship Between IAB and Left Atrial Volume
in the CT Study Population
Two approaches were used to describe the relationship
between IAB and left atrial end-diastolic volume in the CT
study population. First, the direct association between IAB and
left atrial end-diastolic volume were descriptively assessed by
means of a violin plot (comparing medians, interquartile range,
range). Second, to adjust for age and sex differences across IAB
subgroups, we constructed 2 logistic regression models with
IAB as the outcome (yes/no): Model 1 included age and sex and
model 2 included age, sex, and left atrial end-diastolic volume.
AUC was calculated to compare the 2 models.
Results
A total of 343 607 individuals had an ECG recorded at the
Copenhagen General Practitioners’ Laboratory during the
11-year study period, and of these 152 759 (45%)
individuals were eligible for inclusion. Baseline character-
istics of the study population are presented in Table. In
general, the more advanced IAB, the higher burden of
comorbidity. The median follow-up time was 9.2 years
(IQR 6.3–11.3). During follow-up, 12 657 people were
diagnosed with incident AF, 13 497 were diagnosed with
ischemic stroke, 2040 developed a conduction disorder,
and 34 196 died.
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For lead speciﬁc distribution of 1 or 2 biphasic P-waves in
inferior leads, please see Table S3. The most common inferior
lead affected by a biphasic P-wave was lead III.
Association Analyses in the Whole Population
In general, we observed a dose-response association between
the number of biphasic P-waves in inferior leads and the
hazard of the various outcomes investigated (Figure 2). The
associations were particularly strong with respect to devel-
opment of AF and other conduction disorders. For advanced
IAB, the hazard ratio was 3.38 (95% conﬁdence interval [CI],
2.99–3.81) for developing AF, 1.45 (95% CI, 1.23–1.70) for
developing ischemic stroke, 3.27 (95% CI, 2.52–4.23) for
developing conduction disorder, and 1.35 (95% CI, 1.23–1.47)
for all-cause mortality compared with the population without
IAB. The association with the hazard rate of ischemic stroke
was maintained when AF was considered a competing risk
(Table S4). The association analyses considering which
inferior leads were affected by a biphasic P-wave, or
combinations hereof, and the hazard rate of the various
outcomes are presented in Figure S1. In general, the
association with AF, ischemic stroke, and conduction disorder
were particularly strong for combinations involving a biphasic
P-wave in inferior lead II.
Risk Prediction of Atrial Fibrillation and Ischemic
Stroke
Figure 3 displays the differences in AUC for the 10-year
outcomes of AF and ischemic stroke obtained by adding IAB
to conventional risk models for AF and ischemic stroke,
respectively. Adding IAB to a conventional risk model for AF
signiﬁcantly increased AUC for the 10-year risk of AF in both
groups of individuals: with CVD (difference in AUC, 1.09%:
95% CI, 0.43–1.74%) and without CVD at baseline (difference
in AUC, 1.01%: 95% CI, 0.40–1.62%). For ischemic stroke as
outcome, no signiﬁcant changes in AUC for the 10-year
prediction of ischemic stroke in both individuals with and
without CVD at baseline were observed when adding IAB to a
Table. Baseline Characteristics
Characteristics
Interatrial Block
No IAB Partial IAB IAB, One Biphasic P-Wave IAB, Two Biphasic P-Waves
Advanced IAB, Three
Biphasic P-Waves
Total count—n (%) 113 204 (74) 24 403 (16) 11 888 (7.8) 2442 (1.6) 822 (0.5)
Age (y)—median (IQR) 63 (56–72) 65 (58–74) 66 (59–75) 72 (64–80) 78 (71–84)
Women—n (%) 69 199 (61) 12 045 (49) 4838 (41) 999 (41) 379 (46)
Medical history—n (%)
Hypertension 25 995 (23) 7350 (30) 4386 (37) 1035 (42) 377 (46)
Valvular heart disease 359 (0.3) 111 (0.5) 62 (0.5) 23 (0.9) 9 (1.1)
Heart failure 952 (0.8) 302 (1.2) 178 (1.5) 53 (2.2) 38 (4.6)
Ischemic heart disease 7869 (7.0) 2051 (8.4) 1272 (10.7) 296 (12.1) 102 (12.4)
Diabetes mellitus 7306 (6.5) 1669 (6.8) 979 (8.2) 265 (10.9) 121 (14.7)
Hyperthyroidism 1770 (1.6) 420 (1.7) 179 (1.5) 40 (1.6) 14 (1.7)
Anti-platelets 17 655 (16) 4537 (19) 2679 (23) 664 (27) 270 (33)
Obesity 1713 (1.5) 447 (1.8) 296 (2.5) 57 (2.3) 31 (3.8)
Sleep apnea 500 (0.4) 132 (0.5) 103 (0.9) 17 (0.7) 4 (0.5)
CHA2DS2 VASc
0 points 51 428 (45.4) 8846 (36.2) 3675 (30.9) 445 (18.2) 55 (6.7)
1 point 11 650 (10.3) 3528 (14.5) 2087 (17.6) 406 (16.6) 87 (10.6)
≥2 points 50 126 (44.3) 12 029 (49.3) 6126 (51.5) 1591 (65.2) 680 (82.7)
ECG variables
Heart rate (bpm)—median (IQR) 71 (63–80) 71 (63–83) 68 (61–77) 68 (61–76) 70 (62–80)
Left ventricular hypertrophy—n (%) 3910 (3.4) 1415 (5.7) 606 (5.0) 178 (7.1) 59 (7.0)
For all baseline variables, except hyperthyroidism (P=0.56), we found that the observed differences in medians and proportions were statistically signiﬁcantly (P<0.001) different across the
5 IAB-deﬁned subgroups when calculating P for trend. Ischemic stroke is not included in CHA2DS2 VASc since individuals with ischemic stroke were excluded at baseline. ECG indicates
electrocardiogram; IAB, interatrial block; IQR, interquartile range.
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conventional risk model for ischemic stroke. Brier scores were
signiﬁcantly lower for models with IAB compared with
conventional risk models for both AF and ischemic stroke
as outcome.
Absolute Risk of Atrial Fibrillation and Ischemic
Stroke
The median absolute risks of AF and ischemic stroke within
the respective age- and CVD-groups are provided in Figures 4
and 5, respectively. The highest absolute risk of AF was
observed for individuals with advanced IAB (3 biphasic P-
waves) and CVD in the age-group 60 to 70 years. A total of
50% of the individuals in this subgroup developed AF within
10 years of follow-up compared with 10% in those with
normal P-wave. The importance of IAB for individual risk
predictions of AF within 1, 5, and 10 years from ECG
according to different risk proﬁles is illustrated in Table S5.
With stroke as the outcome, the highest absolute risks
were observed in those with advanced IAB (3 biphasic P-
waves) and CVD aged 60 to 70 years and in those with no
CVD aged 80 to 90 years, respectively. In these subgroups,
the absolute risks of developing ischemic stroke during
10 years of follow-up were 20% and 25%, respectively,
Figure 2. Multivariable-adjusted hazard ratios for atrial ﬁbrillation, ischemic stroke, conduction disorder,
and all-cause mortality by interatrial block. CI95 indicates 95% conﬁdence interval; IAB, interatrial block.
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compared with 11% and 16% in those with normal P-wave,
respectively.
For median absolute risk of conduction disorder within the
respective age- and CVD-subgroups, see Figure S2.
Relationship Between IAB and Left Atrial Volume
in the CT Study Population
A total of 5051 individuals had a cardiac CT and ECG obtained
in sinus rhythm. The median age was 59 years (IQR 51–
67 years), and 54% were women. Figure 6A displays the
relationship between varying degrees of IAB and left atrial
end-diastolic volume without taking age and sex into account.
The more advanced IAB, the greater the left atrial end-
diastolic volume. Figure 6B shows the receiving operator
curve for 2 models predicting IAB (yes/no). The AUC was 65%
for the model containing age and sex, whereas the AUC was
70% for the model containing age, sex, and left atrial end-
diastolic volume.
Discussion
In this large ECG population, we: (1) conﬁrmed previous
ﬁndings of an association between IAB and AF and ischemic
stroke; (2) presented novel ﬁndings of an association between
IAB and conduction disorder; (3) found that adding IAB to a
conventional risk model for AF might improve the accuracy of
personalized AF prognosis; (4) found clinically relevant
differences in long-term absolute risks of AF and ischemic
stroke associated with IAB in several subgroups; and (5) found
that adding IAB to a conventional risk model for ischemic
stroke did not improve risk prediction of ischemic stroke on
an individual level.
In line with our results, previous prospective studies of the
general population (N15 000) have also reported an asso-
ciation between advanced IAB (yes/no) and an increased risk
of AF and ischemic stroke.3,4 However; because of a
population of >150 000 individuals, we were able to nuance
these ﬁndings by looking at IAB with 1, 2, or 3 biphasic P-
waves in inferior leads. Interestingly, we found a dose-
response association between severity of IAB and the risk of
AF and ischemic stroke. As evident from Figure S1, the
association with AF, ischemic stroke, and conduction disorder
were particularly strong for combinations involving a biphasic
P-wave in lead II, either isolated or in combination with a
biphasic P-wave in lead aVF. As such, there seems to be a
gradient of pathogenicity, with a biphasic P-wave in lead III or
its combination with a biphasic P-wave in lead aVF (2 biphasic
P-waves) being the most prevalent and associated with better
prognosis compared with biphasic P-waves involving lead II.
To test whether IAB could improve risk prediction of AF
and ischemic stroke on an individual level, we calculated
measures of discrimination. This is important to examine
because an association between a given parameter and
outcome does not necessarily translate into something
meaningful for the individual patient.18 When IAB was added
Figure 3. Differences in area under the curve for the 10-year outcomes of atrial ﬁbrillation and ischemic stroke obtained by adding interatrial
block to conventional risk models for atrial ﬁbrillation and ischemic stroke, respectively, stratiﬁed by the presence or absence of cardiovascular
disease at baseline. AF indicates atrial ﬁbrillation; AUC, area under the curve; CI, conﬁdence interval; CVD, cardiovascular disease at baseline;
IAB, interatrial block; noCVD, no cardiovascular disease at baseline.
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to a model containing several well-established risk factors for
AF, it signiﬁcantly improved AUC by 1%-point for both
individuals with and without CVD at baseline. We believe that
such an impact on AUC, although modest, may have clinical
implications. In contrast, a recent study found no improve-
ment in Ϲ-statistics for PR-interval depression, P wave
duration, P area, or P terminal force, respectively, when
added to a conventional risk model for AF.19 For ischemic
stroke as outcome, no improvement in AUC was observed. As
such, IAB does not seem to add anything in risk prediction of
ischemic stroke on an individual level. For this reason, we
would argue against initiating anticoagulation treatment
merely on the presence of IAB, as speculated previously.4,5
From a clinical perspective, absolute risks are preferable in
comparison to relative risks. As such, we estimated long-term
absolute risks of AF and ischemic stroke in different subgroups
based on IAB. We have presented these results as cumulative
risk taking into account the competing risk of death. This
implies that we are presenting the probability of being alive
and developing a condition. When the absolute risk increased
most for people at intermediate age compared with older age,
it reﬂects a higher risk of the competing risk of death in the
elderly. A total of 50% of the individuals aged 60 to 70 with
CVD and advanced IAB (3 biphasic P-waves) developed AF
within 10 years of follow-up compared with 10% in those with
normal P-wave. Accordingly, the 60- to 70-year-old individual
with CVD and advanced IAB seems to be at an increased risk of
AF that should not be ignored in clinical practice. Interestingly,
patients with IAB and no CVD had a higher risk of AF than
patients with hypertension, valvular heart disease, heart
failure, and/or ischemic heart disease and no IAB. These data
suggest that clinicians may consider monitoring patients with
IAB closely for the occurrence of AF, especially for high-risk
subgroups. This could be in the form of modern technology,
such as different smartphone-dependent devices or other
wearables.20
We found that IAB on average is associated with larger left
atrial end-diastolic volume. However; part of this association
Figure 4. Cumulative incidence curves of interatrial block for the outcome of atrial ﬁbrillation in patients with and without cardiovascular
disease at baseline and stratiﬁed into 10-year age-groups. Predictions were based on multivariable-adjusted Cox models ﬁtted within the
respective age-group and cardiovascular disease group (yes/no). AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; ECG,
electrocardiogram; IAB, interatrial block.
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was driven by higher age in those with advanced IAB compared
with those without IAB. Moreover, it is well documented that
IAB can exist without evidence of left atrial enlargement.1 As
such, the electrocardiographic IAB is probably a composite of
impaired atrial conduction velocity and left atrial enlargement,
both contributing to the observed increased risk of AF.1,21
Figure 5. Cumulative incidence curves of interatrial block for the outcome of ischemic stroke in patients with and without cardiovascular
disease at baseline and stratiﬁed into 10-year age-groups. Predictions were based on multivariable-adjusted Cox models ﬁtted within the
respective age-group and cardiovascular disease group (yes/no). CVD indicates cardiovascular disease; ECG, electrocardiogram; IAB,
interatrial block.
Figure 6. A, Violin plot displaying median, interquartile range, range, and probability density of left atrial
end-diastolic volume for normal P-wave and interatrial block. IAB indicates inter-atrial blockIAB-1, interatrial
block with one biphasic P-wave in inferior leads; IAB-2, interatrial block with 2 biphasic P-waves in inferior
leads. B, Receiving operator curve for the 2 models. In both models, interatrial block (yes/no) is outcome.
AUC indicates area under the curve; LAEDV, left atrial end-diastolic volume.
DOI: 10.1161/JAHA.117.008247 Journal of the American Heart Association 9
Interatrial Block and Atrial Fibrillation Skov et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Limitations
Since our study population only included individuals aged 50
to 90 years, we cannot extrapolate the current ﬁndings to
other age-groups. The reason for excluding individuals
<50 years-old was because of statistical power— few indi-
viduals <50 years have advanced IAB and events of interests.
The study relied on Danish administrative registries about
data on medication use, morbidity and mortality and for some
of the entries we do not know the validity. However, a
registry-based diagnosis of AF has been found to have a
positive predictive value of 93% for electrocardiographically
documented AF.22 High positive predictive values have also
been found for our register-based deﬁnition of heart failure,
ischemic stroke, and hypertension.10
Conclusions
In a large primary care population, we found that IAB is
associated with increased hazards of AF, ischemic stroke,
conduction disorder, and death from all causes. IAB improved
risk prediction of AF on an individual level when added to a
conventional risk model. For many clinically relevant sub-
groups, the risk of AF among those with IAB was increased to
an extent that could guide clinical decision making. For
ischemic stroke as outcome, IAB does not seem to add
anything in risk prediction on an individual level.
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Table S1. Identification of covariates and outcomes. 
Conditions ICD-10 code, procedure, and operation codes 
Hypertension I10, I15 
Heart failure  I50 
Valvular heart disease 
I05, I06, I34, I35 
Procedure and operation codes; KFK, KFM   
Diabetes Mellitus E10, E11, E12, E13, E14 
Ischemic heart disease I20, I21, I23, I24, I25, ICD-8: 410 
Hyperthyroidism E05 
Obesity E66 
Sleep apnea G473 
Vascular disease I700, I702-I709, I21, I22 
Atrial fibrillation  I48 
Ischemic stroke G458, G459, I63, I64, I74 
Conduction disorder I442, I443, I495 
Conduction disorder was a combined endpoint of 3rd degree atrio-ventricular block (I442 and I443) and sick sinus node 
syndrome (I495). ICD-10=International Classification of Disease, 10th revision.  
 
 
 
 
 
 
 
 
Table S2. Identification of covariates and outcomes from drugs. 
Indication  Drugs (ATC code) 
Hypertension 
Alpha blockers: C02A, C02B, C02C, Non-loop diuretics: C02L, C02DA, C03A, C03B, C03D, 
C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52, Vasodilaters: C02DB, C02DD, 
C02DG, C04, C05, Beta-blockers: C07, Calcium blockers: C07F, C08, C09BB, C09DB, ACE-
inhibitors: C09 
Diabetes  Oral antidiabetics: A10B, Insulin: A10A 
Anti-platelets B01AC 
Hyperthyroidism H03B 
Hypertension was defined from discharge diagnosis or as being present if a subject prior to inclusion was treated 
simultaneously with at least two kinds of antihypertensive drugs. Diabetes and hyperthyroidism were defined from 
discharge diagnosis or in case of a purchase of prescription medication used for one of the two diseases. 
ATC=Anatomic Therapeutic Chemical. 
Table S3. Lead specific distribution of one and two biphasic P-waves in inferior leads. 
IAB_lead Frequency Percent 
No IAB 113,204 74.1 
Partial IAB 24,403 16 
One biphasic in II 85 0.06 
One biphasic in III 11,363 7.4 
One biphasic in aVF 440 .29 
Two biphasic in II & III 6 0 
Two biphasic in II & aVF 109 0.07 
Two biphasic in III & aVF 2,327 1.52 
Three biphasic 822 0.54 
Total 152,759 100 
IAB=inter-atrial block. 
 
Table S4. The hazard of ischemic stroke when censoring for atrial fibrillation during follow-up. 
 
 Hazard ratio (95% CI) P-value 
No IAB REF REF 
Partial IAB  1.00 (0.96 – 1.05) 0.885 
IAB, one biphasic P-wave 1.07 (1.00 – 1.13) 0.052 
IAB, two biphasic P-waves 1.17 (1.04 – 1.32) 0.011 
Advanced IAB, three biphasic P-waves 1.32 (1.09 – 1.60) 0.005 
IAB=inter-atrial block; CI=confidence interval.
Table S5. Examples of Absolute Risk Predictions on an Individual Level. 
Patient examples IAB subgroups 
Absolute risk of AF (%) during follow-up from 
index ECG   
  1 year 5 years 10 years 
Woman, 65 years of age, no 
comorbidities, normal heart rate, no 
ECG sign of left ventricular 
hypertrophy 
No IAB 0.5 2.5 6.1 
Partial IAB 0.7 3.3 8.0 
IAB, one biphasic P wave 0.9 4.3 10.4 
IAB, two biphasic P waves 1.5 7.0 16.6 
Advanced IAB, three biphasic P waves 2.9 13.2 29.5 
Man, 65 years of age, no comorbidities, 
normal heart rate, no ECG sign of left 
ventricular hypertrophy 
No IAB 0.7 3.3 7.8 
Partial IAB 0.9 4.4 10.4 
IAB, one biphasic P wave 1.2 5.7 13.5 
IAB, two biphasic P waves 2.0 9.2 21.0 
Advanced IAB, three biphasic P waves 3.9 17.2 35.9 
Woman, 65 years of age, ischemic heart 
disease, hypertension, normal heart rate, 
no ECG sign of left ventricular 
hypertrophy 
No IAB 0.7 3.7 8.9 
Partial IAB 0.9 4.8 11.3 
IAB, one biphasic P wave 1.0 5.2 12.2 
IAB, two biphasic P waves 1.4 7.0 15.9 
Advanced IAB, three biphasic P waves 5.0 23.5 46.3 
Man, 65 years of age, ischemic heart 
disease, hypertension, normal heart rate, 
no ECG sign of left ventricular 
hypertrophy 
No IAB 0.9 4.7 10.8 
Partial IAB 1.2 6.1 13.7 
IAB, one biphasic P wave 1.3 6.5 14.8 
IAB, two biphasic P waves 1.8 8.7 18.9 
Advanced IAB, three biphasic P waves 6.5 28.5 51.4 
Predictions were based on Cox models fitted within the respective age and CVD/no CVD subgroups and adjusted for covariates as 
described in the manuscript. AF=atrial fibrillation; ECG=electrocardiogram; IAB=inter-atrial block 
 
 
 
 
Figure S1. Multivariable-adjusted hazard ratios for atrial fibrillation, ischemic stroke, conduction 
disorder, and all-cause mortality by which inferior leads affected by biphasic P-wave. IAB=inter-atrial 
block; CI95=95% confidence interval. 
 
Figure S2. Cumulative incidence curves for conduction disorder in patients with and without cardiovascular disease at baseline and stratified 
into 10-year age-groups. Predictions were based on multivariable-adjusted Cox models fitted within the respective age-group and cardiovascular 
disease group (yes/no). CVD=cardiovascular disease; ECG=electrocardiogram; IAB=inter-atrial block. 
 
 
